R-2487 in Patients With Rheumatoid Arthritis

This study is testing a new experimental drug called R-2487 in people with active rheumatoid arthritis (RA) — a condition where the immune system mistakenly attacks the joints — to evaluate its safety and potential effectiveness in reducing joint inflammation. **You may be eligible if...** - You are 18 to 75 years old with active RA (confirmed by standard classification criteria) and joint tenderness and swelling despite current treatment - You may continue hydroxychloroquine, methotrexate, or leflunomide during the study - Your steroid dose is stable and low (10 mg prednisone daily or less) **You may NOT be eligible if...** - You are pregnant or breastfeeding - You have another autoimmune disease (e.g., lupus, psoriasis, vasculitis, inflammatory bowel disease) - You have active, latent, or a history of tuberculosis (TB) - You have HIV, active hepatitis B or C - You have had a serious infection requiring hospitalization in the past 60 days - You have had a serious cancer in the past 5 years - You have advanced heart, kidney, or liver disease - You received certain biologic treatments (e.g., rituximab, adalimumab, tocilizumab) recently Talk to your doctor to see if this trial is right for you.